← Browse by Condition
Medical Condition

carcinoma non small cell lung

Total Trials
10
Recruiting Now
10
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for carcinoma non small cell lung sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — carcinoma non small cell lung Clinical Trials

How many clinical trials are currently recruiting for carcinoma non small cell lung?
ClinicalMetric currently tracks 10 actively recruiting clinical trials for carcinoma non small cell lung, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for carcinoma non small cell lung?
carcinoma non small cell lung research spans Phase 1 (4 trials), Phase 2 (3 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a carcinoma non small cell lung clinical trial?
Eligibility criteria for carcinoma non small cell lung trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
3
Phase 3
2
Top Sponsors
Merck Sharp & Dohme LLC 2 trials
Fudan University 1 trial
Janssen Research & Development, LLC 1 trial
Fundación GECP 1 trial
Weill Medical College of Cornell University 1 trial

Recruiting Clinical Trials

NCT03786003
Recruiting
ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
Enrollment
1,086 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT07227025 Phase 1, Phase 2
Recruiting
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Enrollment
60 pts
Location
United States, Canad...
Sponsor
Janssen Research & Development...
View Trial →
NCT06431633 Phase 3
Recruiting
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Enrollment
129 pts
Location
Spain
Sponsor
Fundación GECP
View Trial →
NCT06623656 Phase 2
Recruiting
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Enrollment
112 pts
Location
United States
Sponsor
Weill Medical College of Corne...
View Trial →
NCT06131840 Phase 1
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Enrollment
914 pts
Location
United States, Canad...
Sponsor
Seagen, a wholly owned subsidi...
View Trial →
NCT04165070 Phase 1, Phase 2
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Enrollment
450 pts
Location
United States, Canad...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07161882
Recruiting
ALG-LungCancerRegistry (SAFRO2202)
Enrollment
3,750 pts
Location
Algeria
Sponsor
Société Algérienne de Formatio...
View Trial →
NCT06484491
Recruiting
IMPT Dose Escalation for NSCLC (HyDose)
Enrollment
87 pts
Location
Netherlands
Sponsor
University Medical Center Gron...
View Trial →
NCT06566443 Phase 1
Recruiting
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Enrollment
15 pts
Location
United States
Sponsor
The Methodist Hospital Researc...
View Trial →
NCT06623422 Phase 3
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Enrollment
680 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
View Trial →

Related Conditions

lung diseases (1) resectable lung non small cell carcinoma (1) colorectal neoplasms (1) stomach neoplasms (1) pancreatic ductal adenocarcinoma (1) gastroesophageal junction adenocarcinoma (1) small cell lung carcinoma (1) lung neoplasms (1) carcinoma small cell (1) carcinoid tumor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology